

12-22-99

Docket # PF-0049-2 DIV

A

"Express Mail" mailing label number EL 315 815 124 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231 on 12-10-99

By: Nancy Ramos

Printed: Nancy Ramos

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.53(b)**

Assistant Commissioner for Patents  
Box PATENT APPLICATION  
Washington, D.C. 20231

Dear Sir:

This is a request for filing a **DIVISIONAL** application under 37 CFR 1.53(b) of pending prior application Serial No. 09/196,480, filed on November 19, 1998, which is a divisional application of U.S. application Serial No. 08/567,508, filed December 5, 1995, issued June 22, 1999, as U.S. Patent No. 5,914,393, both entitled A NOVEL HUMAN JAK2 KINASE.

1. X Enclosed is a copy of the prior application, U.S. Application Serial No. 08/567,508 filed December 5, 1995, including the oath or declaration as originally signed.
2. X With regard to the requirement of 37 CFR 1.821(e) which requires that a copy of the Sequence Listing in computer readable form (CRF) be submitted, Applicants state that the computer readable form of the "Sequence Listing" for the instant divisional application is identical with the substitute sequence listing filed December 11, 1997, for Serial No. 08/567,508, filed December 5, 1995, issued June 22, 1999, as U.S. Patent No. 5,914,393, to which priority is claimed. In accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed with the December 11, 1997 substitute sequence listing, as the computer readable form for the instant divisional application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant divisional application.
3. X Cancel in this application original claims 2, 3, and 11-13 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
4. X The inventors of the invention being claimed in this application are: Roger Coleman and Susan G. Stuart.

5. X In accordance with 37 CFR 1.63(d), a copy of the originally signed declaration showing applicants' signatures as filed on March 20, 1996 is enclosed.
6. X Amend the specification by inserting before the first line the sentence: "This application is a divisional application of U.S. application serial number 09/196,480, filed November 19, 1998, which is a divisional of U.S. application serial number 08/567,508, filed December 5, 1995, issued June 22, 1999, as U.S. Patent No. 5,914,393."
7. X The filing fee is calculated below:

Claims	Number Filed	Minus	Number Extra	Other Than Small Entity		Basic Fee
				Rate	Fee	\$760.00
Total Claims	13	-20	0	x \$18		\$ 0
Indep. Claims	1	-3	0	x \$78		\$ 0
___ Multiple Dependent Claim(s), if any				+ \$260		\$ 0

**TOTAL FILING FEE \$ 760.00**

8. \_\_\_ An extension of time in the above-named prior application has been requested and the fees therefore have been authorized in said application.
9. X Please charge Incyte Pharmaceuticals, Inc. Deposit Account No. 09-0108 in the amount of \$760.00.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Incyte Pharmaceuticals, Inc. Account No. 09-0108.

A **duplicate** copy of this Request is enclosed.

10. X New formal drawings are enclosed.
11. X The prior application is assigned of record to Incyte Pharmaceuticals, Inc., recorded on March 25, 1996, at reel 7984/frame 0461.
12. X A preliminary amendment is enclosed.
13. X Also enclosed Return Postcard, Information Disclosure Statement, List of Cited References (1449), copy of previously submitted Certificate, Revocation of Power of Attorney and Appointment of New Attorneys, Submission of Formal Drawings, copy of Substitute Submission Under 37 C.F.R. 1.821-1.825, and copy of previously submitted Substitute Sequence Listing.

14. X The power of attorney of the prior application is to:

Narinder S. Banait	Reg. No. 43,482
Adam Warwick Bell	Reg. No. 43,490
Lucy J. Billings	Reg. No. 36,749
Michael C. Cerrone	Reg. No. 39,132
Diana Hamlet-Cox	Reg. No. 33,302
Colette C. Muenzen	Reg. No. 39,784
Lynn E. Murry	Reg. No. 42,918
Danielle M. Pasqualone	Reg. No. 43,847
Susan K. Sather	Reg. No. 44,316
David G. Streeter	Reg. No. 43,168

- a.     An associate power of attorney is attached.
- b.     Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. X Address all future correspondence to:

**INCYTE PHARMACEUTICALS, INC.**  
**PATENT DEPARTMENT**  
**3174 Porter Drive**  
**Palo Alto, California 94304**  
**Phone: (650) 855-0555, Fax: (650) 849-8886**

Date: December 9, 1999 By: Susan K. Sather  
 Susan K. Sather  
 Reg. No. 44,316  
 Direct Dial Telephone: (650) 845-4646

- Inventor(s)  
    Assignee of complete interest  
X Attorney or agent of record  
    Filed under 37 CFR 1.34(a)  
    Registration number if acting under 37 CFR 1.34(a) \_\_\_\_\_

"Express Mail" mailing label number EL 315 815 124 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231 on 12-10-99

By: Nancy Ramos  
 Printed: Nancy Ramos

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Coleman and Stuart

Title: A NOVEL HUMAN JAK2 KINASE

Serial No.: To Be Assigned Filing Date: Herewith

Examiner: To Be Assigned Group Art Unit: To Be Assigned

**Official Draftsman**

Assistant Commissioner for Patents  
 Box Patent Application  
 Washington, D.C. 20231

**SUBMISSION OF FORMAL DRAWINGS**

Sir:

Transmitted herewith are Figures 1A, 1B, 1C, 1D, 1E, 1F, 1G, 1H, 2A, 2B, 2C, 2D, 2E, as thirteen (13) sheets of formal drawings for this application. Each sheet of drawing indicates the identifying indicia suggested in 37 CFR Section 1.84(c) on the reverse side of the drawings.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Incyte Pharmaceuticals, Inc. Deposit Account No. **09-0108**. **A duplicate copy of this communication is enclosed.**

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,  
INCYTE PHARMACEUTICALS, INC.

Date: December 9, 1999

Susan K. Sather  
Susan K. Sather  
Reg. No. 44,316  
Direct Dial Telephone: (650) 845-4646

3174 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 849-8886